Table 1.
Overview of included studies.
| Trial | Year of Publication | Type of Trial | Years Recruited | Radiotherapy (RT) Technique | Risk Classification | Number of High-Risk (HR) Patients | Prescription Dose | Androgen Deprivation Therapy (ADT) Use in HR Patients |
|---|---|---|---|---|---|---|---|---|
| Kang JK et al. [34] | 2011 | Retrospective | 2002–2007 | CyberKnife (CK) | D’Amico | 29 | 4 × 8–9 Gy | 100% (≥24 months, 2 months neoadjuvant) |
| Oliai C et al. [42] | 2012 | Retrospective | 2007–2010 | CK | D’Amico | 12 | 5 × 7–7.5 Gy | 31% (<6–24 months) |
| King CR et al. [29] | 2013 | Phase II (pooled data) |
2003–2011 | CK | D’Amico | 121 | 5 × 7.25 Gy (median) |
38% 4 months (median) |
| Bolzicco G et al. [30] | 2013 | Prospective database | 2006–2012 | CK | National Comprehensive Cancer Network (NCCN) | 17 | 5 × 7 Gy | N/A |
| Chen LN et al. [41] | 2013 | Prospective database | 2008–2010 | CK | D’Amico | 8 | 5 × 7–7.25 Gy | 11% (3 weeks–36 months) |
| Tree AC et al. [56] | 2014 | Prospective database | 2010–2013 | CK | NCCN | 6 | 5 × 7.25 Gy | N/A |
| Lee SW et al. [48] | 2014 | Retrospective | 2006–2012 | CK | NCCN | 13 | 5 × 7.2 Gy | N/A |
| Janowski E et al. [47] | 2014 | Prospective database | 2008–2011 | CK | D’Amico | 9 | 5 × 7–7.25 Gy | 33.3% |
| Davis J et al. [35] | 2015 | Retrospective | 2006–2015 | CK Linear accelerator (Linac) |
NCCN | 33 | 5 × 7.25 Gy (87%) |
45.5% |
| Rana Z et al. [50] | 2015 | Retrospective | 2008–2014 | CK | D’Amico | 8 | 5 × 7.25 Gy (median) |
N/A |
| FASTR Baumann G et al. [28] |
2015 | Phase I/II | 2011–2017 | Linac | NCCN | 16 | 5 × 8 Gy (prostate) and 5 × 5 Gy (pelvic elective nodal irradiation (ENI)) |
100% (12 months) |
| Fan CY et al. [49] | 2015 | Retrospective | 2010–2013 | CK | NCCN | 16 | 5 × 7.5 Gy | 81% (6–24 months, neoadjuvant) |
| Dixit A et al. [55] | 2016 | Prospective database | 2014–2015 | CK | D’Amico | 6 | 5 × 7.25 Gy | 50% (3–6 months) |
| Kotecha R et al. [45] | 2016 | Prospective database | 2011–2014 | Linac | NCCN | 13 | 5 × 7.25/10 Gy (simultaneous-integrated boost (SIB)) |
No |
| Ricco A et al. [36] | 2016 | Retrospective | 2007–2012 | CK | NCCN | 32 | 5 × 7–7.25 Gy | N/A |
| Katz A et al. [57] | 2016 | Prospective database | 2006–2010 | CK | NCCN | 38 | 5 × 7–7.25 Gy | 55.3% (6 months, neoadjuvant) |
| Koskela K et al. [39] | 2017 | Retrospective | 2012–2015 | CK | D’Amico | 111 | 5 × 7–7.25 Gy | 88.3% (48% for ≥2 years) |
| Murthy V et al. [31] | 2018 | Prospective database | 2014–2017 | Tomotherapy Linac |
NCCN | 68 | 5 × 7–7.45 Gy (prostate) and 5 × 5 Gy (cN1) |
100% (≥2 years) |
| SATURN Alayed Y et al. [26] Musunuru HB et al. [38] |
2018/2019 | Phase I/II | 2013–2014 | Linac | NCCN | 30 | 5 × 8 Gy (prostate) and 5 × 5 Gy (pelvic ENI) |
100% (12–18 months) |
| HYPO-RT-PC Widmark A et al. [23] |
2019 | Phase III | 2005–2015 | Linac | NCCN | 62 | 7 × 6.1 Gy | No |
| FASTR-2 Callan L et al. [27] |
2019 | Phase I/II | 2015–2017 | Linac | NCCN | 28 | 5 × 7 Gy | 100% (18 months, 2 months neoadjuvant) |
| pHART8 Alayed Y et al. [26] |
2019 | Phase I/II | 2011–2013 | Linac | NCCN | 30 | 5 × 6/8 Gy (SIB) |
100% (12–18 months) |
| Zilli T et al. [58] | 2020 | Phase II | 2012–2015 | Linac | NCCN | 29 | 5 × 7.25 Gy | 100% (6 months, 2 months neoadjuvant) |